• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR 3.57% 27.0¢

PARADIGM BIOPHARMACEUTICALS LIMITED.. - News & Media

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No News & Media currently available.

(20min delay)
Last
27.0¢
Change
-0.010(3.57%)
Mkt cap ! $82.30M
Open High Low Value Volume
28.0¢ 28.0¢ 26.5¢ $281.4K 1.024M

Buyers (Bids)

No. Vol. Price($)
1 3499 27.0¢
 

Sellers (Offers)

Price($) Vol. No.
28.0¢ 161588 8
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
27.5¢
  Change
-0.010 ( 1.79 %)
Open High Low Volume
27.5¢ 27.5¢ 26.5¢ 182425
Last updated 15.58pm 21/11/2024 ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.